Amgen’s Otezla faces a hit from Bristol’s would-be rival, but safety data will tell the full story
Celgene needed to sell psoriasis blockbuster Otezla to win an OK to merge with Bristol Myers Squibb, which had a potential rival in the pipeline, and Amgen stepped up with $ 13 billion. Now, that BMS candidate has topped Otezla in a head-to-head study—and Amgen’s quick success with the med could be in jeopardy. In a… Read More »